

In the Claims:

Claim 1 (currently amended) A method for treating a gastrointestinal disorder in a mammal suffering from or susceptible to the disorder, the method comprising administering to the mammal a therapeutically effective amount of a compound represented by any one of Formulae I, III, IV and VI through XIII or a pharmaceutically acceptable salt or solvate thereof ~~that increases nitric oxide (NO) activity as measured in a standard gastric emptying assay.~~

Claim 2 (canceled)

23
Claim 3 (currently amended) The method of claim 1 ~~or 2~~ wherein the mammal has been identified and selected for treatment to increase ~~at least one of the NO activity and the nNOS level,~~ and the compound is then administered to the identified and selected mammal.

Claim 4 (currently amended) The method of claim 1 ~~or 2~~ wherein the amount of the administered compound is sufficient to increase neuronal cyclic guanosine 3'-monophosphate (cGMP) levels as measured by a standard cGMP assay.

Claim 5 (currently amended) The method of claim 1 ~~or 2~~ wherein the gastrointestinal disorder is characterized by hypomotility or hypermotility in at least one of the small intestine, large intestine, colon, esophagus ~~or~~ and stomach.

Claim 6 (currently amended) The method of claim 1 ~~or 2~~ wherein the gastrointestinal disorder is further characterized by at least one of nausea, vomiting, heartburn, postprandial discomfort, diarrhea, constipation, and indigestion.

Claim 7 (currently amended) The method of claim 1 ~~or 2~~ wherein the disorder is associated with at least one of diabetes, anorexia nervosa, bulimia, achlorhydria,

achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma and gastrointestinal damage.

Claims 8-12 (canceled)

Claim 13 (currently amended) The method of claim 1 ~~or~~ 2 wherein the mammal is suffering from or susceptible to Crohn's disease or ulcerative colitis.

Claim 14 (currently amended) The method of claim 1 ~~or~~ 2 wherein the compound is a PDE inhibitor ~~compound is administered~~.

Claims 15-34 (canceled)

03
Claim 35 (currently amended) A method for preventing or treating a diabetic gastropathy in a mammal comprising administering to the mammal a therapeutic amount of one or more of the compounds represented by Formulae I and III through XIII as those formulae are set forth above, or a pharmaceutically acceptable salt thereof.

Claim 36-43 (canceled)

Claim 44 (currently amended) A method for treating a mammal suffering from or susceptible to diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Crohn's disease or ulcerative colitis, comprising administering to the mammal an effective amount of one or more of the compounds represented above by Formulae I, III, IV and VI through XIII as those formulae are set forth above, or a pharmaceutically acceptable salt thereof.

Claims 45-50 (canceled)

Claim 51 (previously amended) The method of claim 44 wherein the mammal has been identified as suffering from diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Chrohn's disease or ulcerative colitis, and the mammal has been selected for treatment for diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Chrohn's disease or ulcerative colitis.

Claim 52 (canceled)

a¹³
Claim 53 (currently amended) The method of ~~elaims~~ claim 1 ~~or~~ 2 wherein the mammal is a human patient.

Claim 54 (currently amended) The method of ~~elaims~~ claim 1 ~~or~~ 2 wherein the mammal has been subjected to or will be subjected to treatment with at least one prokinetic agent.

Claim 55 (currently amended) The method of ~~elaims~~ claim 1 ~~or~~ 2 wherein the method further comprises administering to the mammal a therapeutically effective amount of at least one prokinetic agent.

Claim 56 (previously amended) The method of claim 55 wherein the prokinetic agent is metoclopramide, domperidone, erythromycin or cisapride.

Claim 57 (new) A method for treating a gastrointestinal disorder in a mammal suffering from the disorder, the method comprising administering to the mammal a therapeutically effective amount of sildenafil.

Claim 58 (new) The method of claim 57, wherein the gastrointestinal disorder is characterized by hypomotility or hypermotility in at least one of small intestine, colon and stomach.

Claim 59 (new) The method of claim 57, wherein the disorder is characterized by diarrhea or constipation.

Claim 60 (new) The method of claim 57, wherein the disorder is associated with diabetes.

Claim 61 (new) A method for increasing nNOS or mRNA expression in a gastrointestinal organ comprising administering an effective amount of sildenafil to a mammal in need thereof.

213
Claim 62 (new) The method of claim 61, wherein the patient is a human.

Claim 63 (new) The method of claim 61, wherein the organ is stomach, antrum, pylorus or intestine.

Claim 64 (new) The method of claim 1 or 35, wherein the compound is represented by Formula I or a pharmaceutically acceptable salt or solvate thereof.

Claim 65 (new) The method of claim 1 or 35, wherein the compound is represented by Formula III or a pharmaceutically acceptable salt or solvate thereof.

Claim 66 (new) The method of claim 1 or 35, wherein the compound is represented by Formula IV or a pharmaceutically acceptable salt or solvate thereof.

Claim 67 (new) The method of claim 35, wherein the compound is represented by Formula V or a pharmaceutically acceptable salt or solvate thereof.

Claim 68 (new) The method of claim 1 or 35, wherein the compound is represented by Formula VI or a pharmaceutically acceptable salt or solvate thereof.

Claim 69 (new) The method of claim 1 or 35, wherein the compound is represented by Formula VII or a pharmaceutically acceptable salt or solvate thereof.

Claim 70 (new) The method of claim 1 or 35, wherein the compound is represented by Formula VIII or a pharmaceutically acceptable salt or solvate thereof.

Claim 71 (new) The method of claim 1 or 35, wherein the compound is represented by Formula IX or a pharmaceutically acceptable salt or solvate thereof.

a¹³
Claim 72 (new) The method of claim 1 or 35, wherein the compound is represented by Formula X or a pharmaceutically acceptable salt or solvate thereof.

Claim 73 (new) The method of claim 1 or 35, wherein the compound is represented by Formula XI or a pharmaceutically acceptable salt or solvate thereof.

Claim 74 (new) The method of claim 1 or 35, wherein the compound is represented by Formula XII or a pharmaceutically acceptable salt or solvate thereof.

Claim 75 (new) The method of claim 1 or 35, wherein the compound is represented by Formula XIII or a pharmaceutically acceptable salt or solvate thereof.

Claim 76 (new) A method for treating a mammal suffering from or susceptible to diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Chrohn's disease or ulcerative colitis, comprising administering to the mammal an effective amount of a compound represented by Formula V or a pharmaceutically acceptable salt thereof.
